Skip to main content
Elanix Biotechnologies AG logo

Elanix Biotechnologies AG — Investor Relations & Filings

Ticker · ELN ISIN · DE000A0WMJQ4 LEI · 391200SYNFFL0NPAJK90 F Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2018-04-30 Capital/Financing Update
Country DE Germany
Listing F ELN

About Elanix Biotechnologies AG

https://elanixbiotechnologies.com/

Elanix Biotechnologies AG is a tissue regeneration company that develops and commercializes products for acute wound care, dermatological, and gynecological applications. The company's core focus is on creating therapeutic solutions derived from progenitor cells. Its product development pipeline aims to provide advanced treatments for skin and tissue repair.

Recent filings

Filing Released Lang Actions
Elanix Biotechnologies AG secures up to EUR 2.5 Million SEDA (Standby Equity Distribution Agreement) financing
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' announcement dated April 30, 2018, disclosing that Elanix Biotechnologies AG has secured a Standby Equity Distribution Agreement (SEDA) financing of up to EUR 2.5 Million. The content explicitly discusses securing equity financing, capital increase, and future financing plans involving convertible debt, which are core elements of capital structure changes and fundraising activities. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it mentions a future agreement subject to shareholder approval, the primary focus of this specific announcement is the immediate financing agreement (SEDA). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS) given the specific nature of the content.
2018-04-30 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 41 of the WpHG (German Securities Trading Act). It details a 'Publication of total number of voting rights' and specifies the 'New total number of voting rights' as 7,099,219, resulting from an 'Other capital measure' effective on 19 Feb 2018. This type of announcement, which reports changes in the total number of shares/voting rights, most closely aligns with the 'Share Issue/Capital Change' category (SHA). Although it is a regulatory announcement distributed via DGAP, the specific content is about a capital structure change, making SHA more precise than the general RNS fallback.
2018-02-20 English
Elanix Biotechnologies AG Raises EUR 1.125 Million gross proceeds from Completed Capital Increase and Signs Term-Sheet for Financing Facility of up to EUR 11 Million
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Elanix Biotechnologies AG has completed a capital increase, raising EUR 1.125 million, and signed a term sheet for a larger financing facility. The key subject matter revolves around fundraising, capital structure changes, and the use of proceeds for product development and commercialization. This directly aligns with the definition of 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains substantive financial and strategic news regarding capital activities.
2018-02-14 English
Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of 300,019 shares from the current cash capital increase and signs a Term Sheet for financing facility of up to EUR 11 Million
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated February 14, 2018, detailing two key corporate actions: the placement of shares from a cash capital increase (raising EUR 1.125 million) and the signing of a Term Sheet for a future financing facility of up to EUR 11 Million. These actions directly relate to the company's capital structure, fundraising, and financing activities. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is a specific announcement about capital raising, CAP is the most precise classification.
2018-02-14 English
Elanix Biotechnologies AG Appoints Baader Bank as a New Designated Sponsor and goetzpartners securities for Corporate Broking
Board/Management Information Classification · 99% confidence The document is a press release dated January 23, 2018, announcing that Elanix Biotechnologies AG has appointed Baader Bank as a designated sponsor and goetzpartners securities for corporate broking. This announcement concerns changes in the company's financial representation and market support structure, which relates to capital markets efforts and investor relations. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a management discussion (MDA). It is a specific corporate action announcement related to market making and advisory services. This type of announcement, dealing with corporate structure changes related to market access and advisory roles, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate news item, as there is no specific category for 'Designated Sponsor Appointment'. Given the content is a direct announcement of a corporate event rather than a report, RNS is the most appropriate fallback.
2018-01-23 English
Elanix's Partner Transwell Biotech Completes Phase I of Phase I/II Clinical Trial with Progenitor Cell Treatment for Skin Graft Wounds
Regulatory Filings Classification · 99% confidence The document is a press release dated December 27, 2017, announcing the completion of Phase I of a clinical trial by Elanix's partner, Transwell Biotech, regarding a progenitor cell treatment for skin graft wounds. It details preliminary safety results and outlines plans for Phase II to begin in Q1 2018. This type of announcement, focusing on research updates, study results, and clinical progress, is characteristic of a general corporate news release. Since there is no specific category for 'Research Update' or 'Clinical Trial News' among the provided codes, and it is not a formal financial filing (like 10-K, IR, ER), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous corporate announcements that do not fit elsewhere, especially those disseminated via services like DGAP.
2017-12-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.